Market Overview

UPDATE: Benchmark Raises PT to $18 on Cardiovascular Systems on Improved Visibility

Related CSII
Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks
How To Profit From An Aging Population

Benchmark reiterated its Speculative Buy rating on Cardiovascular Systems (NASDAQ: CSII) and increased its price target from $13.50 to $18.

Benchmark said, "We believe that there is a significant market opportunity in the U.S. for CSII to launch their device in the coronary market during calendar Q1:14. We estimate that CSII will send their clinical data to the FDA during calendar Q1:13 and we expect regulatory approval in the U.S. and subsequent launch during calendar Q1:14. CSII did a modular design with module 1 being preclinical and module 2 being manufacturing/system quality. … Peer comparables trade at a revenue per share multiple of 3 to 5 time and, based on the improved visibility, we are moving our valuation multiple from 3 to 4 times."

Cardiovascular Systems closed at $12.22 on Monday.

Latest Ratings for CSII

May 2014Bank of AmericaInitiates Coverage onBuy
Mar 2014NeedhamInitiates Coverage onStrong Buy
Feb 2014WunderlichTerminatesBuy

View More Analyst Ratings for CSII
View the Latest Analyst Ratings

Posted-In: BenchmarkAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (CSII)

View Comments and Join the Discussion!

Get Benzinga's Newsletters